Highlights and Quick Summary
- Average Common Equity for the quarter ending June 30, 2022 was $24.1 Million (a -25.3% decrease compared to previous quarter)
- Year-over-year quarterly Average Common Equity increased by 175.56%
- Annual Average Common Equity for 2021 was $70.1 Million (a 75.22% increase from previous year)
- Annual Average Common Equity for 2021 was $40 Million (a 378.88% increase from previous year)
- Annual Average Common Equity for 2020 was $8.36 Million (a -14.02% decrease from previous year)
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Average Common Equity of Biofrontera AG Sponsored ADR
Most recent Average Common Equityof BFAGY including historical data for past 10 years.Interactive Chart of Average Common Equity of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Average Common Equity for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | – | $24.08 | $32.24 | – |
| 2021 | $37.51 | $8.74 | $15.66 | $17.8 | $70.11 |
| 2020 | $10.14 | $7.29 | $10.32 | $9.89 | $8.36 |
| 2019 | – | $8.44 | $14.54 | $16.42 | $11.3 |
| 2018 | – | – | – | $9.89 | $19.51 |
| 2017 | – | – | $8.44 | $14.54 | $3.69 |
| 2016 | $16.42 | – | – | – | $17.38 |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic